Testing effectiveness (Phase 2)Looking for participantsNCT04991103
What this trial is testing
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Who this might be right for
Multiple MyelomaAmyloidosis
University of Alabama at Birmingham 40